Journal of Vaccine Research 2024, Vol.14, No.5, 217-230 http://medscipublisher.com/index.php/jvr 229 Kelly H., Sokola B., and Abboud H., 2021, Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients, Journal of Neuroimmunology, 356: 577599-577599. https://doi.org/10.1016/j.jneuroim.2021.577599 PMID: 34000472 PMCID: PMC8095041 Lacaille‐Dubois M.A., 2019, Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review, Phytomedicine, 60: 152905-152905. https://doi.org/10.1016/j.phymed.2019.152905 PMID: 31182297 PMCID: PMC7127804 Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L, .and Gam-COVID-Vac Vaccine Trial Group, 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet (London, England), 397: 671-681. https://doi.org/10.1016/S0140-6736(21)00234-8 PMID: 33545094 PMCID: PMC7852454 Lynn D.J., Benson S.C., Lynn M.A., and Pulendran B., 2021, Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms, Nature Reviews Immunology, 22(1): 33-46. https://doi.org/10.1038/s41577-021-00554-7 PMID: 34002068 PMCID: PMC8127454 Malfertheiner P., Selgrad M., Wex T., Romi B., Borgogni E., Spensieri F., Zedda L., Ruggiero P., Pancotto L., Censini S., Palla E., Kanesa-thasan N., Scharschmidt B., Rappuoli R., Graham D.Y., Schiavetti F., and Giudice G., 2018, Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a cag-positive strain: a randomised, placebo-controlled phase 1/2 study, The Lancet Gastroenterology & Hepatology, 3(10): 698-707. https://doi.org/10.1016/S2468-1253(18)30125-0 PMID: 30042064 Pastural É., McNeil S.A., MacKinnon-Cameron D., Ye L.Y., Langley J.M., Stewart R., Martin L.H., Hurley G.J., Salehi S., Penfound T.A., Halperin S., and Dale J.B., 2019, Safety and immunogenicity of a 30-valent M protein-based group A streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study, Vaccine, 38(6): 1384-1392. https://doi.org/10.1016/j.vaccine.2019.12.005 PMID: 31843270 Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C., and C4591001 Clinical Trial Group, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine,The New England Journal of Medicine, 383(27): 2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMID: 33301246 PMCID: PMC7745181 Saleh A., Qamar S., Tekin A., Singh R., and Kashyap R., 2021, Vaccine development throughout history, Cureus, 13(7): e16635. https://doi.org/10.7759/cureus.16635 PMID: 34462676 PMCID: PMC8386248 Sekuloski S., Batzloff M.R., Griffin P., Parsonage W., Elliott S., Hartas J., O’Rourke P., Marquart L., Pandey M., Rubin F.A., Carapetis J., McCarthy J., and Good M.F., 2018, Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial, PLoS ONE, 13(7): e0198658. https://doi.org/10.1371/journal.pone.0198658 PMID: 29965967 PMCID: PMC6028081 Sharma R., Rajput V., Jamal S., Grover A., and Grover S., 2021, An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins, Scientific Reports, 11: 13836. https://doi.org/10.1038/s41598-021-93266-w PMID: 34226593 PMCID: PMC8257786 Tafreshi S.Y.H., 2020, Efficacy, safety, and formulation issues of the combined vaccines, Expert Review of Vaccines, 19(10): 949-958. https://doi.org/10.1080/14760584.2020.1817551 PMID: 33118470 Wang C.Y., Hwang K.P., Kuo H.K., Peng W.J., Shen Y.H., Kuo B.S., Huang J.H., Liu H., Ho Y.H., Lin F., Ding S.D., Liu Z., Wu H.T., Huang C.T., Lee Y.J., Liu M.C., Yang Y.C., Lu P.L., Tsai H.C., Lee C.H., Shi Z.Y., Liu C.E., Liao C.H., Chang F.Y., Cheng H.C., Wang F.D., Hou K.L., Cheng J., Wang M.S., Yang Y.T., Chiu H.C., Jiang M.H., Shih H.Y., Shen H.Y., Chang P.Y., Lan Y.R., Chen C.T., Lin Y.L., Liang J.J., Liao C.C., Chou Y.C., Morris M.K., Hanson C.V., Guirakhoo F., Hellerstein M., Yu H.J., King C.C., Kemp T., Heppner D.G., and Monath T.P., 2022, A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against delta and omicron variants, The Journal of Clinical Investigation, 132(10): e157707. https://doi.org/10.1172/JCI157707
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==